MedTrace Logo

A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

NCT03401112 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-05-15

Study results available
· View outcomes & findings →

Summary

Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or sickle-β0 thalassemia).

Conditions

Interventions

DRUG

IMR-687

Oral administration of IMR-687 once daily with or without HU.

DRUG

Placebo

Oral administration of placebo once daily with or without HU.

Sponsors & Collaborators

  • Imara, Inc.

    collaborator INDUSTRY

  • Cardurion Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Regulatory Operations · Cardurion Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-26
Primary Completion
2020-08-28
Completion
2020-08-28
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03401112 on ClinicalTrials.gov